A Relative Bioavailability Study of 20 mg Famotidine Tablets Under Fed Condition
Status:
Completed
Trial end date:
2007-12-01
Target enrollment:
Participant gender:
Summary
The study was conducted as an open-label, balanced, randomized, two-treatment, two-period,
two-sequence, single-dose, crossover, bioavailability study comparing famotidine tablets, USP
20 mg manufactured by OHM Laboratories with Pepcid® AC Acid reducer famotidine tablets 20 mg
(containing famotidine 20 mg) distributed by Johnson & Johnson. Merck Consumer Pharmaceutical
Co. Fort Washington, PA 19034 USA under fed conditions.